Literature DB >> 25546608

Embryonic stem cells derived neuron transplantation recovery in models of parkinsonism in relation to severity of the disorder in rats.

Reena Haobam1, Debasmita Tripathy, Navneet A Kaidery, Kochupurackal P Mohanakumar.   

Abstract

6-Hydroxydopamine (6-OHDA)- and 1-methyl-4-phenylpyridinium (MPP(+))-induced hemi-parkinsonism was investigated in relation to the severity of the disorder in terms of behavioral disability and nigral neuronal loss and recovery regarding the number of stem cell-derived neurons transplanted in the striatum. Intra-median forebrain bundle infusion of the parkinsonian neurotoxins and intra-striatal transplantation of differentiated embryonic stem cells (ESCs) were carried out by rat brain stereotaxic surgery. The severity of the disease was determined using the number of amphetamine- or apomorphine-induced rotations, striatal dopamine levels as estimated by high-performance liquid chromatography (HPLC)-electrochemistry, and the number of surviving tyrosine hydroxylase immunoreactive dopaminergic neurons in the substantia nigra pars compacta. Rats that received unilateral infusion of 6-OHDA or MPP(+) responded with dose-dependent, unilateral bias in turning behavior when amphetamine or apomorphine was administered. Rotational asymmetry in both models correlated significantly well with the loss in the number of nigral dopaminergic neurons and striatal dopamine depletion. Transplantation of 2×10(5) differentiated murine ESCs revealed remarkably similar kinds of recovery in both animal models. The survival of the grafted dopaminergic cells in the striatum was better in animals with low-severity parkinsonism, but poor in the animals with severe parkinsonism. Amphetamine-induced rotational recovery correlated positively with an increasing number of cells transplanted in animals with uniform nigral neuronal lesion. These results suggest that disease severity is an important factor for determining the number of cells to be transplanted in parkinsonian rats for desirable recovery, which may be true in clinical conditions too.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25546608      PMCID: PMC4435747          DOI: 10.1089/rej.2014.1626

Source DB:  PubMed          Journal:  Rejuvenation Res        ISSN: 1549-1684            Impact factor:   4.663


  48 in total

1.  Microtransplantation of dopaminergic cell suspensions: further characterization and optimization of grafting parameters.

Authors:  Guido Nikkhah; Christoph Rosenthal; Gero Falkenstein; Alexandra Roedter; Anna Papazoglou; Almuth Brandis
Journal:  Cell Transplant       Date:  2009       Impact factor: 4.064

2.  Staging of serotonergic dysfunction in Parkinson's disease: an in vivo 11C-DASB PET study.

Authors:  Marios Politis; Kit Wu; Clare Loane; Lorenzo Kiferle; Sophie Molloy; David J Brooks; Paola Piccini
Journal:  Neurobiol Dis       Date:  2010-05-31       Impact factor: 5.996

3.  Regenerative therapy in experimental parkinsonism: mixed population of differentiated mouse embryonic stem cells, rather than magnetically sorted and enriched dopaminergic cells provide neuroprotection.

Authors:  Debasmita Tripathy; Poonam Verma; Dominic N Nthenge-Ngumbau; Meghna Banerjee; Kochupurackal P Mohanakumar
Journal:  CNS Neurosci Ther       Date:  2014-06-21       Impact factor: 5.243

4.  Rats with unilateral median forebrain bundle, but not striatal or nigral, lesions by the neurotoxins MPP+ or rotenone display differential sensitivity to amphetamine and apomorphine.

Authors:  Kizhakke M Sindhu; Rebecca Banerjee; Karuppagounder S Senthilkumar; Karuppagounder S Saravanan; B China Raju; J Madhusudan Rao; Kochupurackal P Mohanakumar
Journal:  Pharmacol Biochem Behav       Date:  2006-07-03       Impact factor: 3.533

5.  Behavioral characterization of a unilateral 6-OHDA-lesion model of Parkinson's disease in mice.

Authors:  Ruxandra Iancu; Paul Mohapel; Patrik Brundin; Gesine Paul
Journal:  Behav Brain Res       Date:  2005-07-01       Impact factor: 3.332

Review 6.  Prospects of stem cell therapy for replacing dopamine neurons in Parkinson's disease.

Authors:  Olle Lindvall; Zaal Kokaia
Journal:  Trends Pharmacol Sci       Date:  2009-04-09       Impact factor: 14.819

7.  Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation.

Authors:  Jia-Yi Li; Elisabet Englund; Janice L Holton; Denis Soulet; Peter Hagell; Andrew J Lees; Tammaryn Lashley; Niall P Quinn; Stig Rehncrona; Anders Björklund; Håkan Widner; Tamas Revesz; Olle Lindvall; Patrik Brundin
Journal:  Nat Med       Date:  2008-04-06       Impact factor: 53.440

8.  A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease.

Authors:  C Warren Olanow; Christopher G Goetz; Jeffrey H Kordower; A Jon Stoessl; Vesna Sossi; Mitchell F Brin; Kathleen M Shannon; G Michael Nauert; Daniel P Perl; James Godbold; Thomas B Freeman
Journal:  Ann Neurol       Date:  2003-09       Impact factor: 10.422

Review 9.  L-DOPA- and graft-induced dyskinesia following transplantation.

Authors:  Emma L Lane; Christian Winkler
Journal:  Prog Brain Res       Date:  2012       Impact factor: 2.453

10.  In vitro maturation of dopaminergic neurons derived from mouse embryonic stem cells: implications for transplantation.

Authors:  Bradley Watmuff; Colin W Pouton; John M Haynes
Journal:  PLoS One       Date:  2012-02-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.